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INTRODUCTION
Breast cancer is one of the most common cancers in women
and is second only to lung cancer as a cause of cancer death
(1). In Korean women, breast cancer is the second most
common among all cancers and ranks fifth as a cause of death
(2). Metastatic breast cancer essentially remains incurable and
almost all women so diagnosed will eventually die from their
disease. The median survival time from diagnosis of metastases
is approximately 3 years (3). Systemic treatment with hormonal
therapy or chemotherapy is of significant palliative benefit in
patients with metastatic disease (4,5). Anthracyclines, alkylating
agents, antimetabolites and vinca alkaloids are considered
active agents in the treatment of metastatic breast cancer and
the average response rate is between 20% and 50%. With
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Purpos e: Pac litaxe l is a ve ry effective age nt in the
treatme nt of breas t cance r. Samyang Co rporatio n has
deve loped its own process to produce pac litaxe l in a
large volume us ing plant ce ll culture technology. To
evaluate the efficacy and s afety of Ge nexo l in patie nts
with metas tatic breas t cance rwho have failed to res po nd
to s tandard the rapy, we pe rformed a pros pective , multi-
ce nter phas e II c linical trial.
Materials and Methods : Patie nts with metas tatic breas t
cance r we re inc luded in this s tudy. Enrollees we re
required to have his to log ically co nfirmed breas t cancer
with bidimens ionally meas urable metas tatic dis eas e .
Ge nexo l was adminis te red at 175 mg/m2 as a 3-ho ur
intrave nous infus io n eve ry 3 wee ks . All patie nts were
pre medicated with hydroco rtis o ne , phe niramine maleate ,
and H2 bloc ke r30 minutes prio rto pac litaxe l. We planned
to adminis ter at leas t 4 co urs es of pac litaxe l unles s the re
was diseas e prog res s io n o r unacce ptable toxic ity and to
co ntinue treatme nt up to a total of 6 cours es in cas es
of objective res po ns e fo llowing 4 cours es .
Res ults : The median duration of fo llow-up was 8.9 (2.07
∼13.7) months . Forty-five patie nts we re reg is te red and
43 we re e lig ible . The pe rformance s tatus of patie nts was
ECOG 0∼1 in 39 patie nts (90.7%) and 2 in 4 (9.3%). The
locatio n of metas tas es at the s tart of the s tudy we re the
lung (15 patients ), liver (8 patie nts ), lymph nodes (22
patie nts ), and othe r (7 patie nts ). Among the 40 evaluable
patie nts , 15 patients o btained partial res pons es (PRs )
(37.5%, 95% CI: 22.5∼52.5%). The median duration of
res pons e was 11.67 (4.1∼11.7) months and the median
time to prog res s ion was 7.73 (2.8∼11.7) mo nths . The
median s urvival time was not reac hed at 13.7 mo nths , and
the ove rall s urvival rate at 13.7 mo nths was 70.1%. The
he mato log ic toxic ity was primarily ne utro penia with g rade
3 o r 4 in 10 patients (23.3%). The g rade 3 o r 4 non-
he mato log ic toxic ities inc luded alopec ia (17, 39.5%), mya-
lg ia (2, 4.7%), ne uro pathy (2, 4.7%), and pruritus (1, 2.3%).
Mild hype rs e ns itiv ity reactio n was o bs e rved in 2 patients ,
altho ugh it did not caus e withdrawal of the tes t drug.
Conclus ion: The res ults s ugges t that the Ge nexo l in-
jectio n is an effective anticance r fo rmulatio n fo r the treat-
me nt of metas tatic breas t cance r and toxic ity is acce pta-
ble . (Cancer Res earch and Treatment 2001;33:451 457)
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monotherapy by the above regimen, complete response is rare
and the average duration of response is between 6 and 9 months
(6,7). With combination chemotherapy, the response rate has
been increased without significant prolongation of survival
duration or signs of more severe toxicities (6∼9). Furthermore,
in the case of no response to the above regimen, in particular
with anthracycline, no active regimen had been followed.
Paclitaxel (Taxol ; Bristol-Myers Squibb Company, Prince-
ton, NJ) is a naturally existing substance found in trace amounts
in the bark of Pacific Yew tree (Taxus brevif olia) and semi-
synthetic methods have been used to produce paclitaxel in
commercial quantities. The mechanism of paclitaxel at the ce-
llular level is the stabilization of microtubules by promotion of
a microtubule assembly from the tubulin dimer and prevention
of the multiplication of cancer cells by inhibition of the G2/M
phase (mitosis) (10). The anticancer chemotherapeutic effect
was confirmed in ovarian cancer (11), breast cancer (12,13) and
non-small cell lung cancer (14). In metastatic breast cancer,
paclitaxel has been reported to elicit a 20∼62% response rate
as a first-line therapy and a 4∼32% rate in previously treated
patients (12∼16).
Samyang Corporation has developed its own process using
plant cell culture technology to produce paclitaxel in large
quantities. This form is physically, chemically and biologically
equivalent to commercialized paclitaxel. The injectable for-
mulation of paclitaxel developed by Samyang Corporation is
branded as Genexol (Samyang co, Korea) in Korea. The
chemical structure and molecular weights of Genexol are the
same as standard paclitaxel (SIGMA and INDENA) and the
purity of Genexol bulk is equal to or even higher than Taxol
(17,18). The toxicity and anticancer effect of Genexol and
Taxol are similar in in vitro and in vivo tests. These results
suggest that Genexol may be safe and possess significant
antitumor activity in breast cancer, although the efficacy and
safety of Genexol in patients with breast cancer has not yet
been evaluated by clinical trial.
Therefore, we performed a phase II study of Genexol in
patients with metastatic breast cancer in order to evaluate the
response rate, duration of response, time to progression,
survival and toxicities.
MATERIALS AND METHODS
1) Patients
The trial was conducted from August 1999 to May 2000 and
enrolled patients from 6 hospitals. Patients with histologically
confirmed metastatic breast cancer were eligible for study. They
were required to be between 18 and 70 years of age, have an
ECOG performance status of 0 to 2, have a life expectancy of
more than 12 weeks, and provide written informed consent in
accordance with institutional review board guidelines. Prior
chemotherapy was permitted, providing it was only one (adju-
vant or metastatic disease) or two regimens (one adjuvant and
the other for metastatic) and was completed at least 4 weeks
(6 weeks in the case of treatment with mitomycin C or nitro-
sourea) before entry into the study. Prior taxane therapy and
concurrent palliative radiotherapy were not allowed. Prior
hormonal therapy, immunotherapy, and localized radiotherapy
for disease were permitted.
All patients were required to have clinically or radiogra-
phically measurable disease, and to have adequate renal, hepatic
and bone marrow functions defined as follows: serum creatinine
≤1.5 upper normal limit (UNL); total bilirubin≤1.25 UNL;
absolute neutrophil count (ANC)≥1.5 109/L and platelet
count≥100 109/L, AST and ALT≤3.0 UNL, and alkaline
phosphatase≤3.0 UNL. Pretreatment evaluation was perform-
ed within 3 weeks of therapy initiation and included full hi-
story, physical examination, CBC, biochemical screening pro-
file, chest X-ray, bone scan, site-specific imaging (especially
liver) and quality-of-life assessment.
Patients were ineligible if they had a history of neoplasm of
other than breast carcinoma (excepting nonmelanomatous skin
cancer or curatively treated cervical carcinoma in situ), a his-
tory of ventricular arrhythmias or congestive heart failure, pre-
existing motor or sensory neuropathy more than grade 1 or any
other underlying medical condition that would hinder study
participation. Pregnant or lactating females or patients of child-
bearing potential who did not implement adequate contraceptive
measures were also ineligible.
2) Therapeutic plan
Genexol was supplied by Samyang Corporation as a conce-
ntrated sterile solution for intravenous (IV) administration in a
5 ml vial containing 30 mg of paclitaxel in polyoxyethylated
castor oil and dehydrated alcohol (Cremophor EL/ethanol). The
drug was diluted with either a 0.9% sodium chloride solution
or a 5% dextrose solution to a final concentration of 0.3∼1.2
mg/ml. The solutions were prepared and stored in glass, po-
lypropylene or polyolefin containers. In-line filters (0.2μm,
Sartorius, Germany) were used to filter microprecipitation du-
ring the infusion of Genexol .
The drug was administered within 7 days after subject regi-
stration. The initial dosage of paclitaxel was 175 mg/m2 (in
case of calculated BSA≥2 m2, administered dose was adjusted
as BSA=2 m2) administrated for 3 hours, every 3 weeks. All
patients were premedicated with the following regimen 30 mi-
nutes prior to paclitaxel infusion; hydrocortisone (or corre-
sponding drug) 100 mg IV, pheniramine maleate (or cor-
responding drug) 45.5 mg IV, and cimetidine 300 mg (or
ranitidine 50 mg) IV. In cases of delayed hematopoietic re-
covery at the first day of the next cycle, that is ANC＜1.5
109/L and the platelet count＜100 109/L, paclitaxel admini-
stration was postponed for a maximum of 2 weeks. For a
patient who experienced severe neutropenia (ANC＜0.5 109/
L), thrombocytopenia (platelet＜25 109/L), febrile neutropen-
ia, mucositis with ulcer or severe peripheral nerve disease, the
dose was reduced to 135 mg/m2 from the next cycle. In the
case of recurrent febrile neutropenia or severe infection or
severe drug-related bleeding, the dose was reduced to 110
mg/m2 .
The planned duration of therapy was at least 2 courses unless
disease progression was rapid. We stopped treatment when
there was disease progression or intolerable (grade 3 or 4)
toxicity, and the patients could refuse to continue treatment at
any time.
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3) Response and toxicity assessment
Tumor measurements were assessed every cycle by physical
examination and every other cycle by imaging studies. Patients
with measurable disease receiving at least two courses of
therapy were assessable for response. All responses were
centrally reviewed.
A complete response (CR) was defined as the disappearance
of all clinical evidence of active tumor and absence of di-
sease-related symptoms for a minimum of 4 weeks. Partial
response (PR) was defined as 50% or greater reduction in the
sum of the products of the biperpendicular diameters of all
measurable lesions and no appearance of new lesions for at
least 4 weeks. When there were multiple sites of metastases,
the largest masses (up to five) were considered as the index
lesions. Stable disease (SD) was defined as no change in tumor
size or a less than 25% increase for at least 4 weeks. The
evaluation of SD was accepted only after at least 6 weeks (2
cycles) from the beginning of treatment. Progressive disease
(PD) was defined as the unequivocal appearance of any new
lesions or a greater than 25% increase in the sum of the
perpendicular diameters of any measured lesion or in the
estimated size of a non-measurable lesion.
The clinical period was established at 6 cycles and the
follow-up was performed to identify disease progression and
death of subjects after the end of clinical period. If patients
wanted to continue treatment, the test drug was administered
continuously at the discretion of investigator with the same
examinations as done during the clinical study period.
The duration of response was defined as the period from the
date of response documented to the first confirmed date of
disease progression in patients with partial responses. Time to
progression was defined as the duration from the administration
of Genexol to the confirmation of disease progression. Survi-
val was defined as the duration from the first administration
of Genexol to the confirmed date of death or to the last fo-
llow-up date at the end of the clinical trial for those who
survived the clinical trial. The median survival was calculated
according to Kaplan-Meier method.
The dose intensity (DI), expressed as mg/m2/wk, was defined
as the dose supplied per week and was calculated by summing
each cycle dose in mg/m2 divided by the number of weeks from
the first day of the first cycle to the date of the last cycle plus
a fixed time of 3 weeks.
Data from all patients who received at least one dose of
Genexol injection was included in the safety analysis. The
adverse reactions observed were classified by involved organ
and observed toxicity and were evaluated according to National
Cancer Institute-Canada's Common toxicity grading (NCIC-
CTG) criteria in relation to the test drug. The severity of any
adverse reaction not defined in NCIC-CTG was graded as
1=mild, 2=moderate, 3=severe, 4=very severe .
RESULTS
1) General characteristics of eligible patients (Table 1)
A total of forty-five patients were enrolled in the study and
forty-three subjects were eligible and received Genexol . Two
subjects were excluded before treatment because one subject
had cervix cancer and the other subject had brain metastasis.
The median age of the patients was 47 (range 32∼63) years.
Eighteen (41.9%) patients were premenopausal, 3 patients were
in menopause and others were unknown. Most patients (90.7%)
scored from 0 to 1 in ECOG. The median duration of breast
cancer before the trial was 34.4 (2.33∼190.39) months. Pre-
dominant metastatic sites were the liver (8, 13.8%), lung (15,
34.9%), skin (6, 14.3%), lymph node (22, 51.2%) and breast
(same side; 1, 2.3%). Pathologic diagnosis was ductal carci-
noma in 38 patients (95.0%), lobular carcinoma in 2 patients
(5.0%) and unknown in 3 patients. Positive estrogen receptors
were observed in 9 patients (29%) and positive progesteron
receptors were seen in 10 patients (32.3%). Eighteen patients
(41.9%) had previously undergone radiotherapy and 40 patients
(93%) had received surgery for breast cancer. Twenty-four
patients (55.8%) were exposed to anthracycline. The number of
chemotherapeutic regimens was one (30, 69.8%) or two (13,
30.2%). Sixteen patients (39.0%) had previously received hor-
monal therapy.
2) Treatment administration
Genexol was administered to forty-three patients who had
been registered in the clinical trial. A total of 197 treatment
cycles were delivered with 4.58 cycles per patient. Through the
courses of this study, only one case required a dosage adju-
stment to 135 mg/m2 from the second cycle because of neu-
tropenia. The median cumulative dosage per subject admi-
nistrated was 1050 (175∼1,050) mg/m2 (1,490 mg in total
dose). Two patients were found not to meet inclusion criteria
because of a high level of alkaline phosphatase and concomitant
medication of tamoxifen, respectively. One patient was dropped
because she refused to continue treatment during the first cycle.
As a result, a total of 40 patients were evaluable for response.
Table 1. Patient characteristics
Characteristics
Total number of patients (administered) 43
Age (years) [median (range)] 47 (32∼63)
Performance status ECOG [0/ 1/2] 16/23/4
Predominant metastatic site [No (%)]
Liver 8 (17.8)
Lung 15 (34.9)
Skin 6 (14.3)
Lymph Node 22 (51.2)
Breast 1 (2.3)
Receptor status [No (%)]
Estrogen receptor positive [No (%)] 9 (29.0)
Progesteron receptor positive [No (%)] 10 (32.3)
Prior therapy [No (%)]
Radiotherapy 18 (41.9)
Operation 40 (93.0)
Chemotherapy 43 (100.0)
Anthracycline 24 (55.8)
Hormonal therapy 16 (37.2)
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3) Efficacy results
Among the 40 evaluable patients, fifteen patients (37.5%
(95% CI: 22.5∼52.5)) obtained PRs and eight cases of SD and
17 cases of PD were observed.
We evaluated the impact of various factors (study center,
prior history of therapies, etc.) on the anticancer response rate
(Table 2). Only the duration of breast cancer appeared to
influence the anti-cancer response. The duration of breast
cancer affected the response rate. The group experiencing a
longer period of breast cancer (more than 34.7 months) regi-
stered a higher response rate (52.4%) than the shorter period
group (19.1%); this difference was statistically significant (p=
0.024). A history of radiotherapy (43.5%) or surgery (35.9%) for
breast cancer did not show a significant effect on response rate
(p＞0.05). A prior history of chemotherapy showed no signi-
ficant influence on response rate (p=0.155). Patients with a
prior exposure to anthracycline also showed lower response
(22.7%) than those with no exposure (52.9%) although this was
not statistically significant (p＞0.05). The number of regimen
showed no significant influence on the response rate (p＞0.05).
The median follow-up duration was 8.9 (2.07∼13.7) months.
The median duration of response was 11.67 (4.1∼11.7) months
(Fig. 1) and the median time to progression was 7.73 (2.8∼
11.7) months (Fig. 2).
Eight patients died, the median survival period was longer
than 13.7 months and the overall survival rate at 12 months
was 70.1% (Fig. 3).
4) Toxicity (Table 3)
All forty-three patients who received therapy were assessable
for toxicity. Overall, therapy was well tolerated. Most of the
adverse drug reactions (ADRs) were limited to mild to mo-
derate toxicity and no patients discontinued therapy for
treatment-related adverse events.
The median dose intensity was 70 (51.4∼116.7) mg/m2/
week, which was more than 90% of the expected administered
Fig. 1. Kaplan-Meier estimate of duration of response
Table 2. The factors that affect the response to Genexol
Response
p-value
rate (%)
Age
＜50 10/23 (43.5%) 0.283
≥50 5/ 17 (29.4%)
Performance status (ECOG)
0∼1 13/36 (36.1%) 0.484
2 2/4 (50.0%)
Hormonal receptor
ER ( );( ) 4/8 (50.0%); 6/21 (28.6%) 0.302
PR ( );( ) 5/ 10 (50.0%); 5/19 (26.3%) 0.251
Total ( );( ) 6/ 11 (54.5%); 4/18 (22.2%) 0.161
Chemotherapy
Anthracycline-based 7/22 (31.8%) 0.311
CMF based 8/ 18 (38.9%)
Metastases
Visceral organ 12/27 (44.4%) 0.169
Non-visceral organ 3/ 13 (23.1%)
Duration of breast cancer
＜34.7 months 4/21 (19.1%) 0.024
≥34.7 months 10/ 19 (52.4%)
Fig. 2. Kaplan-Meier estimate of time to progression
Fig. 3. Kaplan-Meier estimate of overall survival
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dose. A total of thirteen cycles were delayed because of the
patients had not fully recovered from hematological toxicity.
Grade 3 and 4 adverse reactions were recorded in 101
treatment cycles (15.2%) and 3 treatment cycles (1.5%), re-
spectively. All grade 4 ADR were neutropenia. Neutropenia
was the most frequent hematologic toxicitiy (30 cycles, 15.2%)
and grade 3 or 4 neutropenia was observed in 13 cycles (6.6%).
Anemia was observed in 6 cycles (3.0%) and grade 3 anemia
in 1 cycle (0.5%).
The most frequent non-hematologic toxicity was myalgia
(34/43, 79.1%), which was followed by alopecia (22/43, 51.2%)
and pruritus (20/43, 26.5%). The grade 3 or 4 non-hema-
tological ADRs were alopecia (17/43, 39.5%), peripheral neuro-
pathy (2/43, 4.7%), myalgia (2/43, 4.7%) and pruritus (1/43,
2.3%). Most of the other non- hematological ADRs were less
severe than grade 3. Nausea and vomiting were the most
common gastrointestinal ADRs (20/43, 46.6%) related to
Genexol and the severity was less than grade 3.
Two patients experienced hypersensitivity reactions at the first
cycle, although following the treatment for hypersensitivity
reactions they recovered and received the drug again. The
severity of hypersensitivity was mild(nausea, vomiting, dizzi-
ness and mild hypotension) and the symptoms were reversed
with IV infusion, antiemetics and hydrocortisone. The rema-
ining drug was diluted to 1,000 ml of 5% dextrose solution or
normal saline and administered slowly for 24 hours; hyper-
sensitivity reactions did not recur.
DISCUSSION
This phase II clinical trial was performed to evaluate the
efficacy and safety of Genexol injection in metastatic breast
cancer patients. Paclitaxel represents the prototype of a novel
class of anticancer agents with a completely new mechanism
of action. The major activity of paclitaxel in metastatic breast
cancer has been confirmed in many previous studies (12∼16).
Holmes et al (12) reported that the use of paclitaxel (250 mg/
m2 continuous infusion for 24 hours every 3 weeks) in breast
cancer patients with prior chemotherapy (adjuvant or primary
chemotherapeutic role) showed a 56% response rate and a
median of 8 months survival duration. Reichman et al (13)
reported that paclitaxel (250 mg/m2 infusion for 24 hours every
3 weeks) used in metastatic breast cancer patients showed a
62% response rate. Previously, our group also reported a 43.3%
response rate and 7.2 months duration of response by paclitaxel
(175 mg/m2 infusion for 3 hours every 3 weeks) in metastatic
breast cancer (16).
The response rate in this study is similar with those of other
clinical trials in terms of response rate using a paclitaxel formu-
lation in metastatic breast cancer in other countries (12,13,16,
19,20). These results suggest that Genexol is a clinically effe-
ctive and equally responsive against breast cancer and that the
Genexol injection, like another paclitaxel formulation, Taxol,
is an effective anticancer chemotherapeutic formulation for
metastatic breast cancer.
We evaluated the influence of baseline characteristics on the
response rate. The median duration of disease appeared to have
an influence on response rate. Patients with a shorter duration
of disease (＜3 months) had a better response rate (51.9%) as
compared to those with a longer duration of disease (p＜0.05).
Our examination of the response rate in patients with a prior
history of radiotherapy or surgery for breast cancer showed no
statistically significant effect on the response rate (p＞0.05). A
prior history of chemotherapy also showed no statistically
significant influence on response rate (p＞0.05). Prior exposure
to anthracycline had no significant effect on response rate (p
＞0.05) and it was similar with the results from other studies
Table 3. Toxicities (NCIC-CTG grading criteria)
Grades [No. of cycles (% of cycles)]
Hematologic toxicity
I II III IV
Neutropenia 3 (1.5) 14 (7.1) 10 (5.1) 3 (1.5)
Anemia 1 (0.5) 4 (2.0) 1 (0.5) 0
Thrombocytopenia 0 2 (1.0) 0 0
Grades [No. of patients (% of patients)]
Non-hematologic toxicity
I II III IV
Nausea/vomiting 14 (32.6) 6 (14.0) 0 0
Diarrhea 5 (11.6) 2 (4.7) 0 0
Elevated liver enzymes 1 (2.3) 5 (11.6) 0 0
Myalgia 8 (18.6) 24 (55.8) 2 (4.7) 0
Arthralgia 3 (7.0) 3 (7.0) 0 0
Peripheral neuropathy 4 (9.3) 15 (34.9) 2 (4.7) 0
Alopecia 2 (4.7) 4 (9.3) 17 (39.5) 0
Pruritus 11 (25.6) 8 (18.6) 1 (2.3) 0
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(16,19,20). The response rate of the anthracyclin-resistant group
in another study was 20∼30% and prior exposure to anthr-
acycline did not affect the response rate by paclitaxel. These
results would suggest an incomplete cross-resistance between
anthracycline and Genexol .
The median survival for patients in this clinical trial cannot
be calculated because of the small number of reported deaths
and short duration of follow-up. The overall survival rate at 1
year was 71.7% and the median survival has not been reached
at 13.7 months. A longer follow-up is required in order to
evaluate the effect of Genexol on the duration of survival.
The optimal effective dose for paclitaxel has not yet been
determined. Because of the time- and concentration-dependency
of paclitaxel, a higher level and longer duration of exposure
to the drug may induce a higher response rate. However, the
higher the dose of paclitaxel that is used, the more drug-
induced ADRs are observed. In previous studies, the dose-
limiting toxicity of paclitaxel was reversible neutropenia and
life-threatening anaphylaxis (12∼14,21,22). Abrams et al (21)
reported the result of using paclitaxel (175 mg/m2 civ for 24
hours every 3 weeks) in metastatic breast cancer patients with
history of 2 or more prior rounds of chemotherapy. This
showed a 23% of response, 45% rate of febrile neutropenia
and a 49% rate of admission, results which suggest that the
anticancer efficacy of paclitaxel was meaningful, although the
resulting ADRs were severe. In a comparison of the efficacy
and safety of two doses (135 vs 175 mg/m2) of paclitaxel (22),
the higher dose increased progression-free survival, but did not
increase the duration of overall survival. Furthermore, more
severe neutropenia was observed in the higher dose treatment
group and 16% of patients reduced their dose because of
prolonged neutropenia. Although grade 3 or 4 ADRs were
observed and some were associated with Genexol , all were
transient and reversible. These results suggest the following: 1)
The efficacy of Genexol is maintained with a dose of 175
mg/m2, and, 2) Genexol induces tolerable and reversible toxi-
city based on a comparison with the results of a previous study
of Taxol (21,22).
The hypersensitivity response is thought to be caused by a
high concentration of Cremophor EL, which can be reduced by
an increase of infusion time and premedication (dexamethasone,
H2 receptor blocker). As mentioned above, Genexol was
infused for 3 hours, not for 24 hours as used to mitigate aga-
inst a hypersensitivity response. In this study, hypersensitivity
reactions were mild, reversible and did not interrupt the study.
This may suggest that Genexol induces less severe hyper-
sensitivity and a 3-hour schedule of paclitaxel can be used
without severe hypersensitivity reaction.
The high individual activities of anthracyclines and pacli-
taxel, and their incomplete clinical cross-resistance make them
an attractive combination for the treatment of metastatic breast
cancer. Encouraging response rates were observed with a
combination of paclitaxel and anthracyclin for metastatic breast
cancer in many phase II trials and in randomized phase III trials
(23∼25). Recently, in a phase III study of doxorubicin/
paclitaxel versus doxorubicin/cyclophosphamide/fluorouracil,
the overall response rate (87%), time to progression (8.3
months) and overall survival (23.3 months) favored patients re-
ceiving the paclitaxel-based therapy (25). Therefore, further stu-
dies concerning the efficacy of a combination regimen inclu-
ding Genexol and anthracycline derivatives in the treatment
of metastatic breast cancer is warranted.
CONCLUSIONS
According to the results obtained in this clinical trial to
determine the safety and efficacy of Genexol in metastatic
breast cancer, Genexol injection is evaluated to be an effective
and safe anticancer drug formulation for the treatment of
metastatic breast cancer.
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